Metformax (Metformin Hydrochloride)

Metformin works by activating AMP‑activated protein kinase, which reduces glucose production in the liver, decreases intestinal glucose absorption, and increases peripheral uptake of glucose into muscle cells, thereby lowering overall blood sugar levels without stimulating insulin release.

The dosage of Metformax is individualized by the prescribing clinician based on the patient’s glycaemic targets, renal function, and tolerability. The prescriber determines the appropriate strength, frequency, and any titration schedule.

Safety data for metformin in pregnancy are limited, and the product’s pregnancy category is unknown. It should only be used during pregnancy if the potential benefit outweighs any risk. Breastfeeding mothers should consult their healthcare provider, as metformin is excreted in breast milk.

To request Metformax, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformax belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause hypoglycaemia when used alone and primarily improves insulin sensitivity, making it a first‑line option in many treatment guidelines.

Metformax should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Metformax is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or acute illness. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformax is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those receiving iodinated contrast studies without adequate hydration.